It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Placental abnormalities have been sporadically implicated as a source of developmental heart defects. Yet it remains unknown how often the placenta is at the root of congenital heart defects (CHDs), and what the cellular mechanisms are that underpin this connection. Here, we selected three mouse mutant lines, Atp11a, Smg9 and Ssr2, that presented with placental and heart defects in a recent phenotyping screen, resulting in embryonic lethality. To dissect phenotype causality, we generated embryo- and trophoblast-specific conditional knockouts for each of these lines. This was facilitated by the establishment of a new transgenic mouse, Sox2-Flp, that enables the efficient generation of trophoblast-specific conditional knockouts. We demonstrate a strictly trophoblast-driven cause of the CHD and embryonic lethality in one of the three lines (Atp11a) and a significant contribution of the placenta to the embryonic phenotypes in another line (Smg9). Importantly, our data reveal defects in the maternal blood-facing syncytiotrophoblast layer as a shared pathology in placentally induced CHD models. This study highlights the placenta as a significant source of developmental heart disorders, insights that will transform our understanding of the vast number of unexplained congenital heart defects.
Placental dysfunction can affect heart development, but the prevalence of this causality has not been well established. Here, the authors use mouse genetic tools to show that the placenta may constitute a significant source of congenital heart defects.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Mohammad, Shuhiba 1
; Lo Vercio, Lucas Daniel 2 ; Devine, Jay 2
; Shalom-Barak, Tali 3 ; Hallgrimsson, Benedikt 2
; Cross, James C. 4
; Sucov, Henry M. 5
; Barak, Yaacov 3 ; Dean, Wendy 2
; Hemberger, Myriam 1
1 University of Calgary, Dept. of Biochemistry and Molecular Biology, Cumming School of Medicine, Alberta Children’s Hospital Research Institute, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697)
2 University of Calgary, Dept. of Cell Biology and Anatomy, Cumming School of Medicine, Alberta Children’s Hospital Research Institute, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697)
3 University of Pittsburgh, Magee-Women’s Research Institute, Dept. of Obstetrics/Gynecology and Reproductive Sciences, Pittsburgh, USA (GRID:grid.21925.3d) (ISNI:0000 0004 1936 9000)
4 University of Calgary, Dept. of Comparative Biology and Experimental Medicine, Faculty of Veterinary Medicine, Alberta Children’s Hospital Research Institute, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697)
5 Medical University of South Carolina, Dept. of Regenerative Medicine and Cell Biology, Division of Cardiology, Dept. of Medicine, Charleston, USA (GRID:grid.259828.c) (ISNI:0000 0001 2189 3475)




